Eupraxia Pharmaceuticals Welcomes New CFO Alex Rothwell

Eupraxia Pharmaceuticals Welcomes New Chief Financial Officer

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology firm, has announced a significant leadership shift with the appointment of Alex Rothwell as their new Chief Financial Officer. This change is effective immediately, following the retirement of longtime CFO Bruce Cousins.

Bruce Cousins Retires, Alex Rothwell Takes Charge

Bruce Cousins, who has served as the CFO of Eupraxia, will transition into a consultancy role temporarily to ensure a smooth transition of responsibilities. This decision is aimed at maintaining continuity during the leadership change.

James Helliwell, CEO of Eupraxia, expressed enthusiasm about Rothwell's return, highlighting his previous tenure as CFO and his experience in capital markets consultancy. Helliwell stated, "Alex brings invaluable experience which will greatly benefit our leadership team, particularly as we move forward with our promising programs including EP-104GI and EP-104AR." Helliwell also commended Cousins for his excellent contributions, emphasizing his role in the company’s successful Nasdaq listing.

Alex Rothwell: A Proven Leader in Biotechnology

Mr. Rothwell is an accomplished business leader with over 25 years of experience in the capital markets and investment banking sectors. He previously held the CFO position at Eupraxia from 2018 to 2021. Prior to his new appointment, he served as a Senior Advisor at Fort Capital Partners, a boutique investment bank in Canada.

His career in capital markets began in 1995, where he gained extensive experience in mergers and institutional equities. Rothwell played key leadership roles at prominent Canadian investment banks and served as President and Executive Director of Macquarie Capital Markets Canada, overseeing its equities business for seven years. In 2015, he relocated to British Columbia.

Vision for Growth and Value Creation

With his new position, Rothwell has expressed a strong belief in Eupraxia's potential to generate significant value for its shareholders. He is particularly keen on enhancing the company’s innovative pipeline, which includes EP-104GI, slated as a leading treatment option for Eosinophilic Esophagitis, as well as EP-104IAR for knee osteoarthritis pain relief.

Rothwell stated, "There’s a lot of unrealized potential within our assets, and I am excited to help the company recognize that value for both patients and shareholders. Our ongoing projects like EP-104GI provide a unique treatment approach, focusing on local drug delivery, which can create a significant impact in the lives of many."

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals is dedicated to developing advanced, locally delivered, extended-release therapies targeting high unmet medical needs. Their proprietary DiffuSphere™ technology allows for precise drug delivery, potentially leading to fewer adverse effects while enhancing the efficacy of existing drugs.

Currently, Eupraxia’s EP-104GI is undergoing a Phase 1b/2a clinical trial known as RESOLVE for Eosinophilic Esophagitis. Their other product, EP-104IAR, aimed at treating knee osteoarthritis pain, recently completed a Phase 2b trial, achieving crucial endpoints for efficacy.

Future Developments and Pipeline Potential

Eupraxia is expanding its pipeline of long-acting formulations that aim to improve upon currently available therapies. With ongoing developments targeting inflammation and pain, the company is poised to play an essential role in addressing critical healthcare challenges. Rothwell aims to leverage his expertise to drive these innovations and reinforce the company’s market position.

Frequently Asked Questions

What does the appointment of Alex Rothwell as CFO signify for Eupraxia?

Rothwell's appointment is expected to bring stability and experience to Eupraxia, enabling the company to advance its strategic initiatives and strengthen its market presence.

What were some contributions of Bruce Cousins during his tenure?

Bruce Cousins played a pivotal role in Eupraxia's successful Nasdaq listing and strengthened the company's financial structure, laying a solid foundation for future growth.

How is Eupraxia planning to utilize its DiffuSphere™ technology?

The DiffuSphere™ technology is aimed at delivering drugs in a more localized manner, enhancing safety and efficacy, potentially transforming existing FDA-approved drugs.

What are Eupraxia's main product candidates currently in development?

Eupraxia is primarily focused on EP-104GI for Eosinophilic Esophagitis and EP-104IAR for knee osteoarthritis, both demonstrating promising results in clinical trials.

What is the company’s vision for its shareholders?

Eupraxia aims to create significant shareholder value through innovative product development and strategic market positioning, with a focus on unmet medical needs.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.